by Truveta Research | Jul 20, 2026 | Featured research, Research
More than 2 in 5 patients (40.3%) initiating oral orforglipron (Foundayo pill) had no prior evidence of GLP-1-based medication use, suggesting early uptake extends beyond patients already receiving injectable therapies. Among patients with prior GLP-1-based medication...
by Truveta staff | Jul 9, 2026 | Research
A study from University of Pittsburgh and Lumbrita used Truveta Data to compare mortality risk across four antipsychotics commonly used off label to treat Alzheimer’s disease. Among 17,004 patients with Alzheimer’s disease, mortality risk differed across medications...
by Truveta Research | Jul 7, 2026 | Research
Adults over 50 showed two clear increases in measles titer testing in 2019 and 2025, concurrent with large outbreaks. Testing rates were generally higher in residents living in urban regions (compared to rural regions) and were highest among adults ages 50–59 for most...
by Truveta Research | Jul 6, 2026 | Featured research, Research
The rate of e-bike and e-scooter injury-related emergency department (ED) visits increased 7.5-fold among children and adolescents (<18 years) between 2023 and May 2026. More than one-third (35.4%) of patients were diagnosed with a head or neck injury. Traumatic...
by Truveta Research | Jun 29, 2026 | Research
Authors: Karen Gilbert Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Nina B Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M Cartwright, MS ⊕Truveta, Inc, Bellevue, WA...
by Truveta Research | Jun 26, 2026 | Research
Most patients (87.1%) with evidence of oral semaglutide for obesity had evidence of their first dose at 1.5 mg, consistent with the manufacturer-recommended starting dose. Timing of dose increases closely mirrored the recommended schedule, with dose increases...
